Substitut	te for form 1449A/PTO		Complete if Known		
			Application Number	10/802,627	
INFO	RMATION DISC	CLOSURE	Filing Date	March 17, 2004	
STAT	EMENT BY AP	PLICANT	First Named Inventor	RUKHMAN, I.	
			Art Unit	1626	
	(Use as many sheets	as necessary)	Examiner Name	Susannah Lee CHUNG	
Sheet	1	of 2	Attorney Docket Number	1662/63303	

	U.S. PATENT DOCUMENTS						
	Examiner		Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant	
	Initials *		Number - Kind Code ² (if known) MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear		
OIP	lu,		US-5,196,444 A	03-23-1993	Naka et al.		
/ 0	Zo		US-5,578,733*	11-26-1996	Shida et al.		
JUL 28	2008		US-2004/0242661	12-02-2004	Rukhman et al.		
JULZO	اللا 1000		US-2005/0059827	03-17-2005	Rukhman et al.		
%	E.		US-5,399,578	03-21-1995	Ciba-Geigy Corp.		
THADE	AL STATE OF THE PARTY OF THE PA						
		<u> </u>					

^{*} Also published as EP 0 668 272

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document		Name of Patentee or Applicant of Cited	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Document		T⁵			
		EP 1 556 363	11-04-2004	Teva Pharmaceutical Ind. Ltd.					
		WO 2004/083192	09-30-2004	Rukhman et al.					
		WO 2004/087681	10-14-2004	Parthasaradhi et al.					
		WO 2004/026487	04-01-2004	Spraying Systems Co.					

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
		CARINI, D. et al., "Nonpeptide Angiotensin II Receptor Antagonists: The Discovery of a Series of N-(Biphenylylmethyl)imidazoles as Potent, Orally Active Antihypertensives", J. Med. Chem., (1991) vol.34, pp. 2525-2547.	
		FRANCOTTE, E. et al., "Development and validation of chiral high-performance liquid chromatographic methods for the quantitation of valsartan and of the tosylate of valinebenzyl ester," J. of Chromatography B, (1996) vol. 686, pp.77-83.	
		KUBO, K. et al., "Nonpeptide Angiotensin II Receptor Antagonists. Synthesis and Biological Activity of Potential Prodrugs of Benzimidazole-7-carboxylic Acids," J. Med. Chem., (1993) vol.36, pp. 2343-2349.	
		SEWALD, N. et al., Peptides: Chemistry and Biology, (2002) pp.154-157.	
		YAMADA, S. et al., "Method for the Racemization of Optically Active Amino Acids," J. Org. Chem., (1983) vol. 48, pp. 843-846.	
		US Pharmacopeial Forum, NovDec. 2003, vol. 29(6), p.1996.	
		US Pharmacopeial Forum, JanFeb. 2006, vol. 32(1), p.150.	

Examiner		Date	
	1		
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. See Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO				Complete if Known			
				Application Number	10/852,627		
INFO	ORMATION	N DISCL	OSURE	Filing Date	March 17, 2004		
STATEMENT BY APPLICANT				First Named Inventor	RUKHMAN, I.		
				Art Unit	1626		
(Use as many sheets as necessary)				Examiner Name	Susannah Lee CHUNG		
Sheet	2	of	2	Attorney Docket Number	1662/63303		

USP Reference Catalog D9
Communication pursuant to Article 96(2) EPC for EP Application No. 04 750 427.9, dated May 3, 2007.
Observations by the third party under Art. 115 EPC for EP Application No. 04 750 427.9, dated February 22, 2007.
Third party observations concerning EP Application No. 04 750 427.9, dated April 18, 2007.
Third Party Observations re EP Application No. 04 750 427.9, dated April 19, 2007.
Caira, Mino. R., "Crystalline Polymorphism of Organic Compounds", Dept. Of Chemistry, (1998), vol. 198, pp. 163-208.
Grant, David J., "Theory and Origin of Polymorphism", Polymorphism in Pharmaceutical Solids, (1999), pp. 1-33.
Guidance for Industry, "ANDAs: Pharmaceutical Solid Polymorphism", U.S. Dept. of Health and Human Services, (2007), pp.1-10.

Examiner Signature	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation

if not in conformance and not considered, Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

Applicant is to place a check mark here if English language Translation is attached.